elevidys - Search News

News

Roche Pauses Commercial and Clinical Use of Elevidys

Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures

Roche discontinued the commercial and clinical use of Elevidys after two cases of fatal acute liver failure. The Swiss pharmaceutical company said Sunday that the dosing of non-am

MarketWatch · 1d

Sarepta Shares Dive on Second Fatal Liver Failure Tied to Elevidys

Sarepta Therapeutics shares dived 42% in premarket trading after the company disclosed a second reported case of acute liver failure that resulted in a death tied to its Duchenne muscular dystrophy treatment Elevidys. Shares were trading around $20.61. The stock is down 70% on the year.

Seeking Alpha · 1d

Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity

Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an analysis of SRPT stock now.

1don MSN

Biotech pauses trial after second patient death linked to gene therapy

Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular ...

1don MSN

Sarepta shares crash as second patient dies after receiving its gene therapy

Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of ...

1don MSN

Second patient death reported with gene therapy for muscular dystrophy

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene ...

17hon MSN

Health Care Roundup: Market Talk

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Sarepta reports second patient death after treatment with Duchenne gene therapy

Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for ...

Health Care Down as Biotech Slides -- Health Care Roundup

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

1don MSN

Sarepta Reports Second Death of Patient Using Its Gene Therapy

Sarepta Therapeutics Inc. said a second patient has died of acute liver failure after being treated with its gene therapy for ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results